Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 17/20 | 0.79 |
| ▸ | AURKA | O14965 | 13/20 | 0.79 |
| ▸ | KDR | P35968 | 11/20 | 0.79 |
| ▸ | TEK | Q02763 | 11/20 | 0.79 |
| ▸ | LCK | P06239 | 8/20 | 0.79 |
| ▸ | TPX2 | Q9ULW0 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265856 | 0.89 | AURKB (1.00) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1264440 | 0.88 | AURKB (1.00) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1264491 | 0.88 | AURKB (1.00) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1264686 | 0.86 | AURKB (0.84) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1264287 | 0.84 | AURKB (0.84) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1265227 | 0.82 | AURKB (0.77) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1265293 | 0.82 | TEK (0.74) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1265662 | 0.81 | AURKB (0.76) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL12895421 | 0.81 | KDR (0.79) | AURKBAURKAKDRTEKLCK | |
| SCHEMBL1265465 | 0.81 | TEK (0.71) | AURKBAURKAKDRTEKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | claimed |